Evidence map›Paper›PMID 31763043›Full record

ArticlePharmacology research & perspectives2019

Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning.

Gideon Koren, Galia Nordon, Kira Radinsky, Varda Shalev

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Pharmacology research & perspectives, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Chloroquine for Covid 19: introducing drug repurposing to medical students.International journal of medical education · 2020
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gideon KorenAriel University Ariel Israel.ORCID 0000-0002-9234-0875
Galia NordonTechnion The Israeli Institute for Technology Haifa Israel.
Kira RadinskyTechnion The Israeli Institute for Technology Haifa Israel.
Varda ShalevMaccabi Institute for Research and Innovation Tel Aviv Israel.
Maccabi Institute for Health Services Research · ILTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite effective medications, rates of uncontrolled glucose levels in type 2 diabetes remain high. We aimed to test the utility of machine learning applied to big data in identifying the potential role of concomitant drugs not taken for diabetes which may contribute to lowering blood glucose. Success in controlling blood glucose was defined as achieving HgA1c levels < 6.5% after 90-365 days following diagnosis and initiating treatment. Among numerous concomitant drugs taken by type 2 diabetic patients, alpha 1 (α1)-adrenoceptor antagonist drugs were the only group of medications that significantly improved the success rate of glucose control. Searching the published literature, this effect of α1-adrenoceptor antagonists has been shown in animal models, where this class of medications appears to induce insulin secretion. In conclusion, machine learning of big data is a novel method to identify effective antidiabetic effects for potential repurposable medications already on the market for other indications. Because these α1-adrenoceptor antagonists are widely used in men for treating benign prostate hyperplasia (BPH) at age groups exhibiting increased rates of type 2 diabetes, this finding is of potential clinical significance.

Indexed as

Machine LearningAdrenergic alpha-1 Receptor AntagonistsBig DataBlood GlucoseData MiningDiabetes Mellitus, Type 2Drug RepositioningElectronic Health RecordsGlycated HemoglobinHumansMaleProstatic HyperplasiaAdrenergic alpha-1 Receptor AntagonistsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanbig data analysisdiabetes type 2glucose controlmachine learningα1‐adrenoceptor antagonist

Identifiers

PMID31763043
PMCPMC6864406
OpenAlexW2991610913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.